The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Partner Company Announces IP

10 Jun 2008 07:00

RNS Number : 2798W
Amphion Innovations PLC
10 June 2008
 



Amphion Innovations plc Partner Company

DataTern announces agreement of first IP license

London and New York10 June 2008 - Amphion Innovations plc (LSE: AMP) ("Amphion"), today announces that DataTern, Inc., has agreed a non-exclusive license of its key database patents to RedHat, Inc. DataTern was recently established and is wholly owned by Amphion in order to commercialise selected intellectual property opportunities, in partnership with its Partner Companies.  As a result, revenues directly attributable to Amphion from the license fee after costs are approximately $800,000.

 

Currently, DataTern is in discussions with a number of major companies over the same patents. The Directors believe that this agreement sets a precedent for such Companies and DataTern's licensing programme has the potential to be an increasing source of future revenues for Amphion and its Partner Companies.

"We are very pleased to grant a non-exclusive license to RedHat," said Joseph R. Flicek, Chief Executive Officer of DataTern, "This is an important first step in building a strong and broad based licensing programme. DataTern's database technologies have utility across many industries."

Richard C.E. Morgan, Amphion's Chief Executive Officer, said: "We are focused on creating shareholder value, and DataTern is another example of how we are able to provide it through the development of good intellectual property over long periods of time. Amphion's Partner Companies currently own or control over 150 separately identified pieces of intellectual property, a number which is growing rapidly each year."

For further information please contact:

Amphion Innovations
Charlie Morgan
+1 (212) 210-6224

Cardew Group

Tim Robertson/ Jamie Milton/Matthew Law 

+44 20 7930 0777

Charles Stanley (Nominated Adviser)

Mark Taylor/ Freddy Crossley

+44 207149 6000

 

About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 10 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

On the web: www.amphionplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRFKLFBVQBLBBV
Date   Source Headline
5th Nov 20071:39 pmRNSResult of EGM
31st Oct 20075:49 pmRNSTotal Voting Rights-Amendment
31st Oct 20072:18 pmRNSTotal Voting Rights
29th Oct 20077:00 amRNSWellGen Series C Financing
12th Oct 20077:30 amRNSIssue of Equity
12th Sep 20077:01 amRNSInterim Results
28th Aug 200710:25 amRNSNotice of Results
22nd Aug 20077:01 amRNSChange of Adviser
16th Aug 20079:31 amRNSRe: AIM Rule 26
14th Aug 20077:00 amRNSFundraising
30th Jul 20077:01 amRNSRe: Series C Financing
12th Jul 20079:19 amRNSPatent Awarded
2nd Jul 20077:01 amRNSPlacing
7th Jun 20077:01 amRNSAGM Statement
21st May 20071:52 pmRNSRe: Symposium
21st May 20071:00 pmBUSApplied Genomics Paves the Way for Improved Prevention, Diagnosis, and Treatment of Disease
14th May 20074:25 pmBUSAmphion Innovations plc (LSE: ''AMP'') Announces First Annual Science & Business Symposium ''Building Market Value from the World of Genetics''
30th Apr 200711:02 amRNSDirector Shareholdings
11th Apr 200711:31 amRNSResearch Update
5th Apr 20071:00 pmBUSAmphion Innovations Partner Company Motif Biosciences Closes $1m Financing
5th Apr 20079:24 amRNSDirector/PDMR Shareholding
5th Apr 20077:01 amRNSRe: Series C Financing
23rd Mar 20072:42 pmBUSPort of Barbados Selects AXCESS to Provide Security Systems for the Cricket World Cup 2007
23rd Mar 20077:01 amRNSRe: Cricket World Cup
15th Mar 20077:01 amRNSFinal Results
26th Feb 20074:44 pmRNSNotice of Results
9th Feb 20077:00 amRNSRe: Financing
16th Jan 20073:25 pmBUSAmphion Innovations, plc Announces Creation of a Gulf-based Joint Venture
16th Jan 20073:19 pmBUSAmphion Innovations, plc Offers Trading Update
16th Jan 20077:01 amRNSJoint Venture
16th Jan 20077:00 amRNSTrading Update
8th Jan 20074:28 pmBUSAmphion Innovations plc Announces Fundraising
8th Jan 20071:08 pmRNSFundraising - Replacement
8th Jan 20077:00 amRNSFundraising
27th Nov 20063:04 pmBUSAmphion Innovations plc Acquires 35% Stake in Manchester Molecular Diagnostic Spin-out Company
27th Nov 20067:00 amRNSAcquires Stake in Company
13th Nov 20062:58 pmBUSAmphion Innovations plc Partner Company Supertron Acquires Spin Systems
13th Nov 20067:01 amRNSAcquisition
7th Nov 200610:24 amRNSRe: Partner Company
2nd Nov 20064:36 pmRNSDirector/PDMR Shareholding
24th Oct 20069:03 amRNSDirector/PDMR Shareholding
14th Sep 20067:00 amRNSWellGen CEO
12th Sep 20067:00 amRNSChange of Adviser
7th Sep 20067:01 amRNSInterim Results
22nd Aug 20064:00 pmRNSFireStar Software, Inc
17th Aug 20067:01 amRNSAdditional Shares Placed
9th Aug 20061:43 pmRNSIssue of Equity
24th Jul 20067:02 amRNSSeries C Financing
12th Jun 20064:58 pmRNSResult of AGM
8th Jun 20067:03 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.